An advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) is meeting on May 19 to discuss whether to recommend COVID-19 vaccine booster shots for children ages 5 to 11, a group that is just 29% vaccinated so far.
Current COVID-19 booster shots have a problem: they last only about four months and appear to have limited efficacy in a vaccinated population. Clearly, a more durable, more efficacious vaccine is needed, but what should it be? The scientific community has not reached a consensus, according to BioSpace.
U.S. FDA advisers to discuss COVID vaccine boosters in April
BNT162b2 (Pfizer and BioNTech), Center for Biologics Evaluation and Research (CBER), COVID-19 booster shots, COVID-19 shots, COVID-19 Vaccines, FDA/Regulatory, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Vaccines and Related Biological Products Advisory CommitteeThe U.S. drug regulator said on March 21 a panel of independent advisers will meet on April 6 to discuss considerations for use of COVID-19 vaccine booster doses.
Pfizer Postpones EUA in Kids Under 5, Will Wait for Full Data
BNT162b2 (Pfizer and BioNTech), Children, Clinical Data, COVID-19 booster shots, Covid-19 Data, COVID-19 shots, COVID-19 Vaccines, Data Monitoring Committee (DMC), Delta Variant (B.1.617.2; India), Emergency Use Authorization (EUA), FDA, Mayo Clinic, NBC, Omicron (B.1.1.529) (South Africa), Survey Data, Vaccines and Related Biological Products Advisory CommitteeOn the day the public and members of the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee were going to get a look at Pfizer and BioNTech’s COVID-19 vaccine data for children under 5 years old, the companies pulled the Emergency Use Authorization (EUA) submission.
The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee recommended emergency use authorization (EUA) for the Pfizer-BioNTech vaccine for children 5 through 11 years of age, with 17 members voting yes and one abstention.
Second J&J COVID shot gets expert backing; FDA looking at lowering age for Pfizer booster
Advisory Committees, BNT162b2 (Pfizer and BioNTech), COVID-19 booster shots, Covid-19 Data, COVID-19 therapeutic candidates, COVID-19 Vaccines, FDA, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, R&D, Vaccines and Related Biological Products Advisory CommitteeOutside advisers to the U.S. Food and Drug Administration on Oct. 15 unanimously recommended the regulatory agency authorize a second shot of Johnson & Johnson’s Covid-19 vaccine for all recipients of the one-dose inoculation.
A panel of expert advisers to the U.S. Food and Drug Administration unanimously voted on Oct. 14 to recommend booster shots of Moderna Inc.’s Covid-19 vaccine for Americans aged 65 and older and those at high risk of severe illness or occupational exposure to the virus.
Pfizer Enters Final Stretch of Late-Stage Covid-19 Vaccine Trial
Analysts, AstraZeneca, BioNTech, Biotechnology Companies, Biotechnology Companies, Clinical Trials, COVID-19 Vaccines, Emergency Use Authorization, Oxford University, Pfizer, R&D, United Kingdom, United States, Vaccines and Related Biological Products Advisory CommitteePfizer indicated that the company’s Phase III clinical trial of 44,000 volunteers with partner BioNTech needed less than 2,000 people to be fully enrolled.
The U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention presented details about Covid-19 and the requirements for a vaccine in a nine-hour virtual meeting.